BTIG Reiterates Buy on Vaxcyte, Maintains $89 Price Target

BTIG analyst Thomas Shrader has reiterated a Buy rating on Vaxcyte (NASDAQ: PCVX) and maintained a price target of $89. This endorsement suggests confidence in the company's future performance in the market.